Ibalizumab Biosimilar – Anti-CD4 D3 domain mAb – Research Grade

Description of Ibalizumab Biosimilar - Anti-CD4 D3 domain mAb - Research Grade

Title: Understanding Ibalizumab Biosimilar: A Promising Therapeutic Antibody Targeting CD4 D3 Domain

Introduction:

Ibalizumab Biosimilar is a monoclonal antibody (mAb) that has shown promising results in treating various diseases. It specifically targets the CD4 D3 domain, making it a highly specific and effective therapeutic option. In this article, we will discuss the structure, activity, and potential applications of Ibalizumab Biosimilar in the field of medicine.

Structure of Ibalizumab Biosimilar:

Ibalizumab Biosimilar is a recombinant humanized IgG4 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a unique structure, with one antigen-binding site and one Fc receptor-binding site. The antigen-binding site is responsible for recognizing and binding to the CD4 D3 domain, while the Fc receptor-binding site allows for interaction with immune cells.

Activity of Ibalizumab Biosimilar:

The primary function of Ibalizumab Biosimilar is to inhibit the interaction between the CD4 receptor and the human immunodeficiency virus (HIV) envelope glycoprotein gp120. This interaction is crucial for the entry of HIV into host cells, and by blocking it, Ibalizumab Biosimilar prevents viral fusion and entry into CD4+ T cells. This mechanism of action makes it a potent antiviral agent, with the ability to suppress viral replication and reduce the viral load in infected individuals.

Applications of Ibalizumab Biosimilar:

Ibalizumab Biosimilar has been primarily studied for its potential use in treating HIV infection. It has shown promising results in both treatment-experienced and treatment-naive patients, with a significant reduction in viral load and an increase in CD4+ T cell count. It has also been studied in combination with other antiretroviral drugs, and the results have been encouraging, with a lower risk of drug resistance and improved treatment outcomes.

Apart from HIV, Ibalizumab Biosimilar has also shown potential in treating other diseases, such as autoimmune disorders and cancer. The CD4 D3 domain is not only present on CD4+ T cells but also on other immune cells, making it a potential therapeutic target for various conditions. Studies have shown that Ibalizumab Biosimilar can modulate the immune response, making it a promising option for diseases like rheumatoid arthritis and multiple sclerosis.

Research Grade Ibalizumab Biosimilar:

In addition to its potential as a therapeutic agent, Ibalizumab Biosimilar is also available in a research-grade form. This allows for further studies and investigations into its structure, activity, and potential applications. Research-grade Ibalizumab Biosimilar can be used in various laboratory assays, such as enzyme-linked immunosorbent assays (ELISA) and flow cytometry, to study its binding affinity, specificity, and biological activity.

Conclusion:

In conclusion, Ibalizumab Biosimilar is a highly specific and effective monoclonal antibody that targets the CD4 D3 domain. Its unique structure and mechanism of action make it a promising therapeutic option for HIV and other diseases. Its availability in research-grade form also allows for further studies and potential applications in the field of medicine. With ongoing research and clinical trials, Ibalizumab Biosimilar has the potential to improve the lives of many individuals and make a significant impact in the treatment of various diseases.

Ibalizumab Biosimilar - Anti-CD4 D3 domain mAb binds to Human CD4 in indirect ELISA Assay

Immobilized CD4 Protein - T-cell surface glycoprotein CD4(CD4) (cat. No. PX-P4702) at 0.5µg/mL (100µL/well) can bind Ibalizumab Biosimilar - Anti-CD4 D3 domain mAb (cat. No. PX-TA1174) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 2.551M.

Ibalizumab Biosimilar - Anti-CD4 D3 domain mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.